Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model All three major indices are trading up today with the Dow Jones Industrial Average ( ^DJI) trading up 81 points (0.5%) at 15,076 as of Thursday, June 13, 2013, 12:55 PM ET. The NYSE advances/declines ratio sits at 2,136 issues advancing vs. 827 declining with 99 unchanged. The Health Services industry currently sits up 0.4% versus the S&P 500, which is up 0.6%. Top gainers within the industry include Edwards Life ( EW), up 3.5%, Medtronic ( MDT), up 1.4%, Covidien ( COV), up 1.3%, Smith & Nephew ( SNN), up 1.1% and HCA Holdings ( HCA), up 0.9%. On the negative front, top decliners within the industry include St Jude Medical ( STJ), down 0.58, and DaVita HealthCare Partners ( DVA), down 0.60. TheStreet Ratings group would like to highlight 4 stocks pushing the industry higher today: 4. C.R. Bard ( BCR) is one of the companies pushing the Health Services industry higher today. As of noon trading, C.R. Bard is up $2.62 (2.49) to $107.73 on average volume Thus far, 332,910 shares of C.R. Bard exchanged hands as compared to its average daily volume of 636,100 shares. The stock has ranged in price between $105.18-$107.77 after having opened the day at $105.30 as compared to the previous trading day's close of $105.11. C. R. Bard, Inc. designs, manufactures, packages, distributes, and sells medical, surgical, diagnostic, and patient care devices worldwide. C.R. Bard has a market cap of $8.4 billion and is part of the health care sector. The company has a P/E ratio of 18.6, above the S&P 500 P/E ratio of 17.7. Shares are up 7.5% year to date as of the close of trading on Wednesday. Currently there are 5 analysts that rate C.R. Bard a buy, 2 analysts rate it a sell, and 10 rate it a hold. TheStreet Ratings rates C.R. Bard as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, notable return on equity, largely solid financial position with reasonable debt levels by most measures, increase in stock price during the past year and expanding profit margins. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full C.R. Bard Ratings Report now. 3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.